Is EXEL or GILD more undervalued in 2026?

CirclFi compares Exelixis, Inc. (EXEL) and Gilead Sciences, Inc. (GILD) using 13 institutional-grade valuation models. EXEL has a Quality of Company score of 10.0/10 while GILD scores 10.0/10.

Which is a better buy — EXEL or GILD?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do EXEL and GILD valuations compare?

EXEL at $50.48 and GILD at $134.43 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

EXEL vs GILD Valuation Comparison 2026 — Intrinsic Value Analysis

EXEL

Biological Products, (No Diagnostic Substances)

Exelixis, Inc.

Quality

10.0

out of 10

Value Trap

SAFE

Price

$50.48

Last close

Models

12/13

Active

GILD

Biological Products, (No Diagnostic Substances)

Gilead Sciences, Inc.

Quality

10.0

out of 10

Value Trap

SAFE

Price

$134.43

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	EXEL Fair Value	EXEL Upside	GILD Fair Value	GILD Upside
Bayesian DCF	Intrinsic	$27.56	-45.4%	$76.95	-42.8%
Earnings Power Value	Intrinsic	$29.37	-41.8%	$65.99	-50.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for EXEL vs GILD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EXEL vs GILD — Which Stock Is More Undervalued?

Both EXEL and GILD score 10.0/10 on quality. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Exelixis, Inc. (EXEL) and Gilead Sciences, Inc. (GILD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EXEL currently trades at $50.48 with a QOC of 10.0/10, while GILD trades at $134.43 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).